Partnership Seeks to Accelerate Development of Innovative Therapies
Approval marks first oral therapy for MCL patients, and a new option for patients with unmet medical need
Anti-CD20-Interferon Alpha Fusion Protein is a promising therapy for NHL patients resistant to standard therapy
Check out our Blog! Mission: Possible
Media Contacts:
If you're a member of the media, you can direct all inquiries for The Leukemia & Lymphoma Society's (LLS's) Indiana Chapter to email amy.kwas@lls.org or call 317.860.3840.